You are viewing the site in preview mode

Skip to main content

Table 3 AD-PRSs versus log plasma p-tau181 in Aβ-positive and Aβ-negative individuals

From: Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative

  APOE PRS Non-APOE PRS
  Aβ pos (n = 322)
PRS version β SE 95% CI p β SE 95% CI p
34-SNP PRS 0.10 0.03 0.05–0.15 7e−5 0.06 0.02 0.01–0.10 0.02
5e−8 PRS 0.10 0.03 0.05–0.15 9e−5 0.05 0.02 0.01–0.10 0.02
1e−5 PRS 0.10 0.03 0.05–0.15 2e−4 0.05 0.02 − 0.001 to 0.09 0.06
PHS* 0.10 0.03 0.05–0.22 2e−4 0.09 0.04 0.01–0.17 0.02
  Aβ neg (n = 409)
β SE 95% CI p β SE 95% CI p
34-SNP PRS 0.15 0.04 0.07–0.23 2e−4 0.01 0.03 − 0.05 to 0.08 0.7
5e−8 PRS 0.17 0.04 0.09–0.25 5e−5 0.04 0.04 − 0.04 to 0.10 0.3
1e−5 PRS 0.14 0.04 0.06–0.22 1e−3 −0.003 0.03 − 0.07 to 0.06 0.9
PHS* 0.14 0.04 0.06–0.15 1e−3 0.08 0.08 − 0.07 to 0.24 0.3
  1. Results are adjusted for sex, age, principal components, and diagnostic status. Significant p values are shown in bold
  2. *Values presented in the “non-APOE PRS column” are adjusted for ε4-carriership instead of excluding APOE
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193